Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04224753 · ClinicalTrials.gov registry record · NA
INVSENSOR00027 Fall Detection Clinical Performance Study
A NA study, sponsored by Masimo Corporation.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT04224753: Completed NA study, sponsored by Masimo Corporation.
NCT04224753 is a NA study that has completed, run by Masimo Corporation. The registered enrollment target is 51 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04224753, a NA study, has completed, sponsored by Masimo Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
This study assesses INVSENSOR00027's clinical performance for fall detection.
Primary Outcome
For each subject's fall simulation, INVSENSOR00027 output will be computed. In order to calculate sensitivity of the device, true positives and false negatives need to be accounted for. For each event of fall, the sensor's output is observed. Fall that is correctly identified is marked as true positive (TP), whereas a missed detection is marked as false negative (FN). Combining the two, test sensitivity is computed by multiplying TP by 100 and dividing that over the sum of TP and FN.
Interventions
- DEVICE INVSENSOR00027
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-12-11 |
| Est. Completion | 2019-12-19 |
| Phase | NA |
What the finished NCT04224753 record still lists
NCT04224753 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which INVSENSOR00027 is the first listed.
NCT04224753 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04224753 about?
NCT04224753 is a clinical study titled "INVSENSOR00027 Fall Detection Clinical Performance Study". This study assesses INVSENSOR00027's clinical performance for fall detection.
What is the current status of trial NCT04224753?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2019-12-11. Estimated completion is 2019-12-19.
What interventions are being tested in trial NCT04224753?
The interventions under investigation include: INVSENSOR00027 (DEVICE).
Who is sponsoring clinical trial NCT04224753?
This trial is sponsored by Masimo Corporation, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04224753's enrollment target sits among peer trials
51 1279th of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI